Over the past several years, the world has faced a series of unprecedented challengespublic health crises, climate change, racial and socioeconomic tensionsthat have intensified the ongoing epidemic of substance use and overdose. The Clinical Manual of Addiction Psychopharmacology, now in its third edition, asserts that substance misuse and addictive disorders, although complex in origin, are inherently treatable.
This new edition is rich in information and practical guidance tailored to today's addiction psychiatry and addiction medicine workforce. The volume is organized by substance classsuch as nicotine and tobacco, alcohol, cannabis, opioids, stimulants, and hallucinogensoffering quick access to essential information. Expert contributors synthesize the latest scientific advancements in how these substances affect those who misuse them, as well as the psychopharmacological and neurobiological bases for available treatments.
This updated edition also features four new chapters: Treatment of Substance Use Disorders: An examination of the pharmacotherapy of addictive disorders through a broader system-based and social lens Behavioral Addictions: An exploration of emerging treatments for non-substance-related addictive disorders such as gambling disorder Integrative Approaches to Addiction Treatment: A comprehensive review of treatment literature on nonstandard pharmacotherapies, including herbal supplements Circuit-Based Interventions for Substance Use Disorders: A description of interventional approaches that include transcranial magnetic stimulation and deep brain stimulation
Other chapters have been updated to reflect the changing social and clinical landscape in which clinicians practice. Additionally, epidemiological review has been intentionally minimized throughout the manual to allow readers to focus on the state of research and clinical treatment recommendations.
The Clinical Manual of Addiction Psychopharmacology, Third Edition, is a foundational, accessible resource for all those who seek to support the clinical needs of their patients and communities.
Chapter
1. Dedication,
Chapter
2. Preface,
Chapter
3. DSM5 Explanation
(Not sure if we want this as part of preface or its own chapterIm open to
suggestions),
Chapter
4. Treatment of Substance Use Disorders,
Chapter
5.
Nicotine and Tobacco,
Chapter
6. Alcohol,
Chapter
7. Cannabis and
Cannabinoids,
Chapter
8. Opioids,
Chapter
9. Stimulants,
Chapter
10. Sedative
Hypnotics,
Chapter
11. Hallucinogens and Phencyclidine,
Chapter
12. Club
Drugs and Inhalants,
Chapter
13. Behavioral Addictions,
Chapter
14.
Integrative Medicine Approaches to Substance Use Disorders,
Chapter
15.
Interventional Psychiatry Approaches to Substance Use Disorders
Jeffrey DeVido, M.D., M.T.S., is Volunteer Assistant Clinical Professor in Psychiatry at the Weill Institute for Neurosciences, University of California, San Francisco; Chief of Addiction Services of Marin County, California; and Behavioral Health Clinical Director with Partnership HealthPlan of California in San Francisco.
Carla Marienfeld, M.D., is Clinical Professor and Addiction Psychiatry Fellowship Director in the Department of Psychiatry at the University of California in San Diego.
Henry R. Kranzler, M.D., is Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine in Philadelphia.
Petros Levounis, M.D., M.A., is Professor and Chair of the Department of Psychiatry and Associate Dean for Professional Development at Rutgers New Jersey Medical School and Chief of Service at University Hospital in Newark, New Jersey.
